Investment Thesis
Strong 18% revenue growth is undermined by deteriorating profitability—net income declined 1.5% and diluted EPS fell 40% YoY despite top-line expansion. Thin 3.0% net margin and 5.5% operating margin indicate margin compression from cost pressures, while low ROA of 3.5% suggests capital deployment challenges. The solid balance sheet and positive $10.2M free cash flow provide stability, but the fundamental disconnect between growth and earnings quality warrants cautious positioning.
Strengths
- Strong 18% YoY revenue growth indicating solid market demand in laboratory apparatus sector
- Conservative balance sheet with 0.30x debt-to-equity ratio and robust 10.9x interest coverage ratio
- Healthy liquidity position with 2.12x current ratio and consistent free cash flow generation of $10.2M
Risks
- Profitability deterioration despite growth—net income down 1.5% and EPS down 40% YoY signals cost pressures exceeding pricing power
- Dangerously thin margins of 3.0% net and 5.5% operating provide minimal buffer against business disruptions or demand changes
- Very low return ratios (3.5% ROA, 8.8% ROE) indicate inefficient capital deployment and limited shareholder value creation
- Significant EPS decline despite revenue growth suggests either share dilution, operational inefficiency, or unfavorable cost structure
Key Metrics to Watch
- Operating margin trend and gross margin sustainability to identify source of profitability deterioration
- SG&A expenses as percentage of revenue—tracking cost discipline relative to top-line growth
- Free cash flow stability and capital intensity requirements in coming quarters
Financial Metrics
Revenue
210.6M
Net Income
6.2M
EPS (Diluted)
$2.09
Free Cash Flow
10.2M
Total Assets
176.0M
Cash
8.2M
Profitability Ratios
Gross Margin
28.1%
Operating Margin
5.5%
Net Margin
3.0%
ROE
8.8%
ROA
3.5%
FCF Margin
4.8%
Balance Sheet & Liquidity
Current Ratio
2.12x
Quick Ratio
1.45x
Debt/Equity
0.30x
Debt/Assets
58.8%
Interest Coverage
10.87x
Long-term Debt
21.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-12T01:45:26.527802 |
Data as of: 2026-01-31 |
Powered by Claude AI